Publicacións en colaboración con investigadores/as de National and Kapodistrian University of Athens (12)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 7, pp. 1934-1948

  2. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2732-2747

2022

  1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 5, pp. 1202-1216.e23

  2. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

    Journal of Asthma and Allergy, Vol. 15, pp. 63-78

2021

  1. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  2. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

    Chest

2020

  1. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  3. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

  4. International severe asthma registry (ISAR): Protocol for a global registry

    BMC Medical Research Methodology, Vol. 20, Núm. 1

2019

  1. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 2, pp. 578-588.e2